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The XII Congress of the Hungarian Society of Nuclear Medi-
cine was held in Gyula, a lovely small town in the south-east of
the country. The scientific committee selected 72 papers for oral
presentation and 29 papers for poster presentation. Information
about latest developments was presented by Prof. Biersack,
Germany (Oncology), Prof. Clausen, Germany (Instrumentation),
Prof. Cuocolo, Italy (Cardiology), Prof. Grünwald, Germany (Neu-
rology), Prof. Kirchner, USA (Project application) and Prof. Lind,
Austria (PET). The programme was completed by round tables
on sentinel lymph node and on radiation protection in nuclear
medicine.
Instrumentation
Mediso, the leading representative of Hungarian manufac-
turers, presented the results of their recent developments. The
palette for routine diagnostics is now completed by a dual-head-
ed gamma camera. In addition, dedicated gamma cameras for
heart and brain SPECT studies have also been introduced re-
cently.
Regarding processing software, Kari and co-workers report-
ed on their positive experience with the new SPECT-oriented pack-
age of Mediso. This software is mainly intended for routine diag-
nostic purposes.
Karman and co-workers in Balatonfüred have collaborated for
many years with the Institute of Biophysics in Strasbourg on the
development of a nuclear stethoscope. Dr Karman reported on
extensions of the software recently implemented and announced
a commercially available product for the near future.
Several working groups reported on their experience with in-
tra-operative probes for sentinel lymph node detection in different
malignancies. Furthermore, Duffek and co-workers from Semmel-
weis University, Budapest, presented promising results in the sup-
porting surgical exploration of parathyroid adenomas. Based on
the data of 48 patients, they concluded that, by using the probe,
operation time can be reduced and the number of successful ex-
cisions can be increased.
Radiopharmacy
The motors of radiopharmaceutical development in Hungary
are the Frederic Joliot Curie National Research Institute for Radio-
biology and Radiohygiene, and the Institute of Isotopes. Both com-
panies co-operate with research groups at universities, national
institutes or big hospitals.
The Institute of Isotopes and the Institute of Nuclear Medicine
of the Medical University in Szeged presented the successful re-
productive synthesis and pre-clinical testing of TRODAT, a Tc-99m-
-labelled tracer for the investigation of the dopamine transporter
system.
A further area of tracer development is the radiopharmaceuti-
cal background for palliative therapy, using the generator product
Rhenium-188. The Szeged group presented promising results
using the generator of the Oak Ridge National Laboratory. The
Institute of Isotopes reported on the testing of different kits for
labelling with Rhenium-188.
One of the main research topics in the Joliot Curie Insti-
tute is the production of labelled monoclonal antibodies. Ja-
noky and co-workers reported on the pre-clinical therapeutic
and clinical diagnostic results with their labelled anti-CEA
monoclonal antibody. The Iodine-131-labelled antibody exhib-
ited a remarkable immuno-reactivity of 80% and successful
inhibition of tumour growth in mouse. The Tc-99m-labelled
antibody was clinically tested by Földes and co-workers. This
group reported good image quality and successful detection
of recurrent colorectal carcinoma, primary breast cancer and
its lymph node metastases.
Further presentations of the Joliot Curie Institute reported on
preliminary results with the technetium labelling of the serotonin
1A receptor antagonist WAY 100636 and of low density lipopro-
teine.
The PET-group in Debrecen presented its Fluorine-18-FNE-
CA, a tracer for adenosine receptors. Pre-clinical investigations
demonstrated a promising tracer distribution accomplished by fast
kinetics.
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Methodical development
Initial experiences with transmission-based non-uniform atten-
uation correction were reported by Nagy and co-workers from Sem-
melweis University. They demonstrated that attenuation correc-
tion leads to enhanced reliability in the analysis of posterior perfu-
sion defects.
Zambo and co-workers from the University of Pecs observed
clinical signs of cerebral ischaemia after dipyridamole test. Re-
peated investigations combined with brain perfusion SPECT dem-
onstrated regional perfusion defects correlating with the clinical
symptoms. They concluded that dipyridamole test may be suit-
able for early detection of subclinical cerebral ischaemia.
Györke and co-workers from Semmelweis University analy-
sed the results of antigranulocyte antibody scintigraphy of the ab-
domen. They found surprisingly frequent unspecific bowel activi-
ty, which may decrease the specificity of the method in this area.
Aspects of radiation protection in connection with lung venti-
lation studies were the topic of a presentation from Szeged Uni-
versity. Sera and co-worker concluded that the application of ra-
dioactive aerosols in the investigation room does not increase
absorbed dose of the personnel significantly.
Quality assurance
Several groups reported the results of retrospective analysis
after therapeutic interventions. Konrady and co-workers analysed
199 patients after treatment of single autonom thyroid nodules.
174 patients had become euthyroid after the first therapy, a sec-
ond therapy was necessary in 12 cases, and 13 patients turned
out to be hypothyroid.
Szentesi and co-workers checked the efficacy of radiosyn-
ovectomy 7 years after therapy and documented good or excel-
lent results in 70% of 213 patients.
There are considerable efforts in Hungary to introduce quality
management systems corresponding to ISO 9001:2000 in nucle-
ar medicine departments. On behalf of the Hungarian Society of
Nuclear Medicine, a Quality Management Handbook is in prepa-
ration in order to give orientation for interested physicians. J. Gom-
bos summarised the requirements of the certification in an excel-
lent paper.
Clinical investigations
Several authors presented results of clinical investigations in
large patient numbers.
Bartfai et al. demonstrated, that early surgery can be prevent-
ed in about 50% of infants with clinical suspect hydronephrosis
when using functional renal scintigraphy.
Földes and co-worker demonstrated that in patients with PSA
level below 15 ng/ml whole body bone scan does not yield any
additional clinical information and can usually be omitted.
The group of the National Institute of Neurosurgery pre-
sented the results of ictal brain perfusion SPECT. Kadar et al.
demonstrated that this sophisticated method can indeed be
performed on a routine basis in optimally organised clinical
structures.
The PET centre in Debrecen reported in several presentations
about clinical experience with FDG. Corresponding to others, ex-
cellent performance has been attested for fluorine-18-FDG PET in
non-small cell lung carcinoma and medullary thyroid cancer. In
patients with germ cell tumours a positive predictive value of 77%
was documented.
In a co-operative study with the University of Freiburg, Györke
et al, from Semmelweis University, Budapest, reported on the re-
sult of FDG-PET in bone malignancies. The method offered addi-
tional information compared to the bone scan in several cases,
however its clinical place is still to be defined.
Clinical research
High-level routine diagnostic work is mandatory for effective
clinical research. Dibo and co-workers from the University of
Szeged reported on brain perfusion SPECT studies in patients
with Parkinson syndrome. They concluded that in Parkinson dis-
ease the frequency of regional perfusion defects is low, whereas
in Parkinson syndrome it is high.
Galuska et al. from Debrecen University investigated cardiac
innervation using Iodine-123-MIBG in patients with neurocardio-
gen syndrome and documented regional abnormalities in this
patient group.
Szekeres et al. from Szeged University performed Iodine-123-
-IBZM brain scans in patients treated with Quetiapine and found
that the effectiveness of treatment can be prognosticated by this
method.
Basic research in medicine
Several presentations documented that nuclear medicine can
find a definitive place in basic research.
Balogh et al. from the Joliot Curie Institute used spontaneous
tumours in dogs for modelling of human disease in testing of new
therapeutic and diagnostic pharmaceuticals.
Szilvasi et al. from Semmelweis University documented that in
Graves ophthalmopathy the number of somatostatine receptors
of leukocytes is more increased than in Graves patients without
clinically manifesting ophthalmophathy.
Multi-drug resistant tumours were the topic of the work of Krasznai
et al. from Debrecen University. Comparing C-11-methionin and F-18-
FDG, they concluded that the activity of the p-lypoproteine can be
demonstrated by increased FDG-accumulation. The difference be-
tween MDR and non-MDR tumours disappears by blocking the p-
lypoproteine and is increased after stimulation.
Finally, the most prospective tendencies of Hungarian nucle-
ar medicine can be demonstrated by the image of the first human
study with Tc-99m-TRODAT from Szeged University (Fig. 1). This
image represents the innovative power of university research
groups in close co-operation with industrial partners. Only these
joint efforts can ensure the continuous development of nuclear
medicine in research and in clinical patient care.
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Figure 1. Dopamine transporter scintigraphy using Tc-99m-TRODAT. Transverse (A) and coronal (B) slices of the healthy volunteer.
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